Introducing NTx Services: Revolutionizing Next-Gen mRNA Research
Nature’s Toolbox (NTx) has launched NTx Services, providing high-integrity, complex mRNA production using its innovative NTxscribe® RNA manufacturing system....
Tivic Health Study Ready for Enrollment With Non-Invasive Vagus Nerve Stimulation Technology
Tivic Health has received approval for the next phase of clinical research on its non-invasive cervical vagus nerve stimulation...
Azitra Gets Fast Track for EGFRi-Associated Skin Toxicity
Azitra, a biopharmaceutical company specializing in precision dermatology, has announced the FDA’s Fast Track Designation for ATR-04, a novel...
Fasenra: A Breakthrough in Treating Eosinophilic Granulomatosis with Polyangiitis
AstraZeneca‘s FASENRA (benralizumab) has received FDA approval for treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune...
New Zeposia Data Reveal Durable Efficacy and Unwavering Safety in Relapsing MS
According to new data, a Phase 3 extension study of Zeposia for multiple sclerosis (MS) found a sustained decrease...
FDA Approves Keytruda® Plus Pemetrexed and Platinum Chemotherapy for Malignant Pleural Mesothelioma
The U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, as a...
Where Parexel Stands on The Future of Clinical Trials
At the 2024 DPHARM Conference, we had the chance to interview Peyton Howell, CEO of Parexel, and she shared...
Real-World Data in Clinical Trials: Benefits & Privacy Risks
The landscape of clinical trials is experiencing a paradigm shift with the integration of Real-World Data (RWD). Traditionally conducted...
Why Innovation in Big Pharma Is So Slow: Insights from BMS
At the 2023 DPHARM conference, Hassan Kadhim from Bristol-Myers Squibb offered an insightful look into the challenges driving innovation...
AstraZeneca and Moffitt Cancer Center: Oncology Cell Therapy Collaboration
Moffitt Cancer Center and AstraZeneca have forged a strategic partnership to advance the development of cell therapies, particularly CAR-T...